• Arena Pharmaceuticals Inc., of San Diego, filed an 8-K with the SEC amending data released for its Phase Ib study of APD811, an oral prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension, to include reports of a serious adverse event.